From Concept to CommercializationÂ
Volorena is a global pharmaceutical innovation and R&D alliance focused on transforming scientific ideas into market-ready healthcare solutions.
We bring together expertise in advanced formulation development, novel drug delivery systems, nanotechnology, regulatory strategy, intellectual property, technology transfer, and commercialization.
Our mission is simple: Innovating Medicines. Advancing Healthcare. Delivering Scientific Excellence.
What We Do?
- Pharmaceutical R&D & formulation development
- Novel and advanced drug delivery systems
- Lipid-, polymer- and nano-based technologies
- Patient-centric and value-added formulations
- Nutraceutical & cosmeceutical development
- Regulatory & IP support
- Technology transfer & scale-up
- Global commercialization & strategic partnerships
Our Vision
To accelerate the journey from scientific innovation to accessible, high-quality healthcare solutions worldwide.
Our Strength
Science + Innovation + Global Collaboration + Commercialization
The Synergy:
Volonium Pharma & Sorena Exir LLP
LEADERSHIP
Dr. Jill Shukla
Founder & Director | Volonium Pharma | Co-Founder / Strategic Leader, Volorena
Brief profile highlighting pharmaceutical R&D, lipid-based drug delivery, innovation, and global healthcare initiatives.
Dr. Moein Masjedi
Founder & CEO | Sorena Exir LLP | Co-Founder / Strategic Leader, Volorena
Brief profile highlighting pharmaceutical research, formulation innovation, advanced drug delivery, patented innovations, and international scientific collaboration.
Short Bio:
Pharmaceutical researcher and innovation leader with expertise in advanced formulation development and novel drug delivery systems. His work focuses on translating pharmaceutical research into innovative, scalable and commercially relevant healthcare solutions, with particular expertise in lipid-based technologies, nanotechnology and advanced formulation platforms.
Key Expertise
- Advanced pharmaceutical formulation
- Lipid-based drug delivery systems
- Niosomes & liposomes
- Nanotechnology-based delivery
- Complex hydrogels
- Translational pharmaceutical R&D
- Pilot-scale formulation development
- Academic–industry collaboration
- Scientific innovation & product development
Two Leaders, One Integrated Ecosystem
Volonium Pharma Strengths:
- Global network and commercial partnership channels.
- Deep regulatory insight across international markets (FDA, EMA, and regional bodies).
- Portfolio management, market research, and licensing expertise
Sorena Exir LLP Strengths:
- Cutting-edge formulation research lab and pilot capacity.
- Specialized expertise in lipid-based systems, niosomes, and complex hydrogels.
- Academic-industry translational research focus.
